Red Cross reps visit captured Cambodian soldiers
A statement testifying to this and describing the captives as "prisoners of war" was released on Tuesday by the army's spokesteam.
Army and Foreign Affairs officials took Bangkok-based representatives of the International Committee of the Red Cross (ICRC) to visit the 18 Cambodian prisoners of war at a detention facility of the 2nd Army Region.
The statement said the ICRC is an international humanitarian organisation that directly supervises the conditions of prisoners of war.
The visit complied with the ICRC's normal work process and had nothing to do with any demand made by Cambodia, the statement said. The ICRC intended to witness the conditions the prisoners were being kept in and put them in communication with their respective families.
The visit also showed Thailand strictly observes international humanitarian principles, especially the Geneva Convention of 1949, and transparently respects the human dignity of prisoners of war.
The army said it let ICRC officials meet and talk freely with the captured Cambodian soldiers, without any time limit and without the presence of Thai officials and journalists, as the ICRC requested.
The army also provided details of the prisoners' health examinations to the ICRC, showing the captured Cambodians were not tortured or mistreated.
The army also informed the ICRC of the situations leading to the detention of 20 Cambodian soldiers and the treatment and repatriation of two of them.
The 18 Cambodian soldiers were healthy and were not injured, the army statement said. They received three meals a day, stayed in a safe and hygienic place and were closely cared for by doctors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bangkok Post
11 hours ago
- Bangkok Post
Chula Licenses Thai PD-1 Antibody to US Biopharma
Bangkok, August 6, 2025 — Chulalongkorn University has entered a landmark licensing agreement with US-based biopharmaceutical company OncoSynergy Inc., transferring the technology behind its innovative Thai-developed PD-1 antibody that could offer new hope in advancing next-generation cancer immunotherapy. The signing ceremony took place at the CU Innovation & IP Expo 2025, hosted by the university on August 4, 2025. Professor Dr. Wilert Puriwat, President of Chulalongkorn University, stated that OncoSynergy's decision to pursue the licensing agreement reflects its strong confidence in the quality and potential of Chula's PD-1 antibody research. This reaffirms Chulalongkorn's strategy not merely to keep pace with global trends, but to lead with innovations that meet world-class standards. Associate Professor Dr. Jittima Luckanagul, Executive Director of Strategic Research Advancement and the CU Innovation Hub, noted that this marks the first time a foreign company has licensed a novel drug innovation originating from Thailand. She added that OncoSynergy recognises the high potential of the university's research to advance into clinical trials and, ultimately, new drug registration an effort that may require an investment of between USD 500 million and 1 billion. In addition to the licensing fee, the university will gain valuable experience in the new drug registration process through collaborative research with OncoSynergy. The US-based company is a clinical-stage immuno-oncology firm dedicated to significantly improving outcomes for patients battling the most aggressive forms of cancer. Under this collaboration, if OncoSynergy successfully develops a new drug based on Chulalongkorn University's PD-1 antibody innovation, the parties have expressed a shared intention to explore mechanisms that would help ensure Thai patients have access to the therapy at a reasonable price. Dr. Trairak Pisitkun, Director of the Center of Excellence in Systems Biology at the Faculty of Medicine, Chulalongkorn University, shared that the centre began its research into cancer immunotherapy nearly a decade ago, supported by funding from the university, government agencies, and public donations. At the time, immunotherapy was an emerging and promising approach to harness the patient's immune system to fight cancer. Today, it has become a cornerstone of cancer treatment, encompassing three major modalities: cell-based therapies, cancer vaccines, and monoclonal antibodies many of which have since gained regulatory approval from health authorities worldwide. Dr. Trairak noted that preclinical studies of the novel PD-1 monoclonal antibody in multiple mouse tumour models demonstrated strong efficacy against solid tumours. Compared to commercially available PD-1 antibody drugs, the candidate exhibited superior PD-1 binding activity, with a lower dissociation constant (Kd), indicating tighter target engagement. In head-to-head assays, it outperformed most existing PD-1 antibodies in both binding affinity and PD-1/PD-L1 blockade. However, the path from successful animal studies to human clinical trials and ultimately to regulatory approval and commercial availability is long, complex, and capital-intensive. Chulalongkorn University anticipates that the full development process will take at least five years and require an investment of several hundred million US dollars. To accelerate this journey, the university has partnered with OncoSynergy, leveraging the company's experience in advancing novel immunotherapies toward clinical application. Immunotherapy is gaining global recognition for its ability to harness the body's own immune system to fight cancer, offering a more precise and potentially less toxic alternative to traditional treatments such as chemotherapy and radiotherapy. Dr. Trairak explained that PD-1 antibody drugs do not directly kill cancer cells, but instead work by blocking the PD-1 immune checkpoint a protein that suppresses the immune system's response to cancer. By inhibiting this pathway, the drugs help restore the immune system's ability to recognise and attack cancer cells. These antibodies are typically used in combination with other treatments including immunotherapies, surgery, radiation, or chemotherapy tailored to each patient's needs. He added that other forms of immunotherapy include CAR-T cell therapy, which engineers a patient's own T cells to better target cancer, and cancer vaccines, which train the immune system to recognise tumour-specific antigens for more effective elimination. The novel PD-1 antibody platform was a highlight of the CU Innovation & IP Expo 2025, underscoring Chulalongkorn University's growing leadership in cutting-edge cancer immunotherapy. The event showcased the university's ability to translate advanced biomedical research into globally competitive innovations. Professor Dr. Wilert Puriwat, President of Chulalongkorn University, emphasised that the CU Innovation Expo is more than a display of inventions it serves as a vital platform to build a strong research and innovation ecosystem in Thailand. 'This is not merely an exhibition of Chula's work,' he stated, 'but a call to action for Thai entrepreneurs to recognise the value of homegrown innovations that meet international standards of research and development.' The PD-1 antibody project represents a national milestone, demonstrating that Thailand is capable of producing world-class therapeutic innovations. The Expo featured over 50 standout innovations across five sectors food & agriculture, health & wellness, design, deep tech, and environment and attracted more than 200 companies. Chulalongkorn University is actively fostering partnerships between Thai companies, startups, and researchers through business matching and licensing opportunities. Partners benefit from unique advantages, including tax incentives and intellectual property privileges, while gaining access to world-class research teams at the university. 'We aim to position our research not only to keep pace with the world, but to deliver real impact practical innovations that serve the Thai people at every level of society,' Prof. Wilert concluded. 'This reflects the university's evolving role not just in education, but in driving economic growth and generating global value from Thai innovations.'
Bangkok Post
2 days ago
- Bangkok Post
Red Cross reps visit captured Cambodian soldiers
International Red Cross representatives on Tuesday visited 18 captured Cambodian soldiers and witnessed the good care being given them by the Thai army, according to the Royal Thai Army.. A statement testifying to this and describing the captives as "prisoners of war" was released on Tuesday by the army's spokesteam. Army and Foreign Affairs officials took Bangkok-based representatives of the International Committee of the Red Cross (ICRC) to visit the 18 Cambodian prisoners of war at a detention facility of the 2nd Army Region. The statement said the ICRC is an international humanitarian organisation that directly supervises the conditions of prisoners of war. The visit complied with the ICRC's normal work process and had nothing to do with any demand made by Cambodia, the statement said. The ICRC intended to witness the conditions the prisoners were being kept in and put them in communication with their respective families. The visit also showed Thailand strictly observes international humanitarian principles, especially the Geneva Convention of 1949, and transparently respects the human dignity of prisoners of war. The army said it let ICRC officials meet and talk freely with the captured Cambodian soldiers, without any time limit and without the presence of Thai officials and journalists, as the ICRC requested. The army also provided details of the prisoners' health examinations to the ICRC, showing the captured Cambodians were not tortured or mistreated. The army also informed the ICRC of the situations leading to the detention of 20 Cambodian soldiers and the treatment and repatriation of two of them. The 18 Cambodian soldiers were healthy and were not injured, the army statement said. They received three meals a day, stayed in a safe and hygienic place and were closely cared for by doctors.
Bangkok Post
2 days ago
- Bangkok Post
Thailand hopes key meeting will ease border tensions with Cambodia
Thailand expects border tensions with Cambodia to improve after the General Border Committee (GBC) meeting planned for later this week. Officials of both countries started talks on Monday, preparing an agenda for talks between the two defence ministers on Thursday. Deputy Defence Minister Gen Nattaphon Narkphanit, who will represent Thailand in the absence of a defence minister, said he was hoping the military confrontation along the border would ease up after the much-anticipated meeting in Kuala Lumpur. Thai negotiators will give priority to protecting the national interest and carefully consider any counter offers from Cambodia, he said. Thai officials convened in the Malaysian capital on Monday for negotiations with their Cambodian counterparts on the framework for the ministerial level meeting on Thursday. The Thai team included representatives from the armed forces, police, and the Defence and Foreign ministries, according to the Defence Ministry. The GBC meeting is aimed at ending the border clashes, which briefly continued even after the two prime ministers agreed to a ceasefire at a meeting in Putrajaya, the Malaysian administrative capital, on July 28. Malaysia stepped in as current chair of the Association of Southeast Asian Nations, with the United States and China also represented at the one-day meeting. The two countries have traded a war of words since the truce announcement. The clashes killed 17 Thai civilians and injured 38, damaged or affected the work of 20 main hospitals and 149 smaller health promotion hospitals, according to the Public Health Ministry. Fifteen Thai soldiers have been killed and scores more injured since the armed conflict began on July 24. Gen Nattaphon said Thai negotiators will end the preparatory talks on Wednesday and their conclusions will be sent to the National Security Council for approval before he meets with Cambodian Defence Minister Gen Tea Seiha on Thursday.
